Market Overview

Jefferies' Picks For 2017's Most And Least Likely Biotech M&A Targets

Jefferies' Picks For 2017's Most And Least Likely Biotech M&A Targets

The total number of M&A deals dipped a bit in 2016, but total deal value surged 44 percent to $218.9 billion. With interest rates still historically low and the U.S. economy still firing on all cylinders, 2017 will likely be another strong year for M&A deals.

One sector that may be particularly ripe for buyouts is the discounted biotech sector, which had a tough year in 2016. With many of these stocks trading at a discount to where they were a year ago, biotech M&A interest may start to pick up soon.

Jefferies analyst Brian Abrahams is cognizant of slowing volumes and increasing competition in the space, but he still believes that there will be plenty of biotech deals this year.

“We see a stabilizing political backdrop and increasingly pro-industry regulatory environment offsetting some of the negativity, and believe an uptick in M&A should catalyze momentum particularly for mid-caps and help improve mixes sentiment,” Abrahams explains.

A survey of buy-side investors found that the most likely biotech buyout targets in 2017 are Incyte Corporation (NASDAQ: INCY), TESARO Inc (NASDAQ: TSRO) and Actelion Ltd (OTC: ALIOF).

The survey suggests the least likely biotech M&A targets include Gilead Sciences, Inc. (NASDAQ: GILD), Intercept Pharmaceuticals Inc (NASDAQ: ICPT) and Ionis Pharmaceuticals Inc (NASDAQ: IONS).

Latest Ratings for GILD

Jul 2019MaintainsNeutral
Jul 2019MaintainsStrong Buy
Jul 2019UpgradesOutperformTop Pick

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas M&A News Analyst Ratings Trading Ideas General Best of Benzinga


Related Articles (GILD + ALIOF)

View Comments and Join the Discussion!

'Becoming Warren Buffett': Your Chance To Get Up Close With The Oracle Of Omaha

Execs Giving CES Keynote Speeches Could Create Volatility For Shareholders